Can nonsteroidal anti-inflammatory drugs (NSAIDs) be used safely during pregnancy, and if so, what are the recommended timing, dosage limits, and preferred alternatives?

NSAID Use in Pregnancy

NSAIDs should be avoided during pregnancy, particularly around conception and after 20 weeks gestation, with use only considered acceptable for short-term, low-dose treatment in the second trimester when maternal benefits clearly outweigh fetal risks. 1

Timing-Specific Recommendations

Periconception and First Trimester (Avoid)

• NSAIDs block blastocyst implantation and significantly increase miscarriage risk, particularly when used around conception 1, 2
• Women actively trying to conceive should avoid all NSAIDs 1
• NSAID use around conception increases miscarriage risk with an adjusted hazard ratio of 1.89 (95% CI: 1.31-2.71), with a dose-response relationship: HR 1.85 for ≥15 days of use 2
• The risk is especially pronounced for early miscarriage (<8 weeks): adjusted HR 4.08 (95% CI: 2.25-7.41) 2
• Women with lower BMI (<25 kg/m²) are particularly vulnerable (adjusted HR 3.78) compared to higher BMI women 2

Second Trimester (Use with Extreme Caution)

• Short-term use (<7 days) as analgesic or antipyretic appears to pose minimal fetal risk 3
• Second trimester use is considered "reasonably safe" but has been associated with fetal cryptorchism 4
• Long-term use in late second trimester requires ultrasound monitoring for oligohydramnios 5
• Any use should be at the lowest effective dose for the shortest duration possible 6

Third Trimester (Contraindicated)

• NSAIDs must be discontinued 6-8 weeks before term 1
• After 30 weeks gestation, NSAID use carries significant fetal risks 4:
  • Premature closure of ductus arteriosus with potential persistent pulmonary hypertension 1, 4, 6
  • Oligohydramnios and fetal renal injury 1, 5, 4
  • Impaired fetal renal function and reduced urine output 1
  • Increased cutaneous and intracranial bleeding 1
  • Necrotizing enterocolitis 4

Maternal Third Trimester Risks

• Prolonged gestation and labor from prostaglandin synthesis inhibition 1
• Increased peripartum blood loss and anemia 1

Monitoring Requirements

If NSAIDs are used beyond 48 hours in pregnancy, ultrasound monitoring of amniotic fluid is mandatory 5:

• Monitor deepest vertical pocket (DVP) and amniotic fluid index (AFI)
• Stop therapy immediately if AFI decline is detected 5
• Oligohydramnios is reversible after NSAID discontinuation 5

Specific Agent Considerations

• Indomethacin, naproxen, ketoprofen, and ibuprofen have all demonstrated adverse fetal effects near term 1
• Low-dose aspirin is an exception: considered safe throughout pregnancy for specific indications (preeclampsia prevention, antiphospholipid syndrome) without increased maternal or neonatal morbidity/mortality 1

Breastfeeding Guidance

Ibuprofen, indomethacin, and naproxen are considered safe during breastfeeding per the American Academy of Pediatrics 1:

• Only trace amounts appear in breast milk 1
• Contraindicated when breastfeeding a neonate with jaundice due to bilirubin displacement 1
• Avoid large doses of aspirin due to salicylate intoxication and bleeding risk in neonates 1
• Low-dose aspirin is generally acceptable 1

Preferred Alternatives

Acetaminophen is the preferred analgesic throughout pregnancy when anti-inflammatory effects are not required 1, 2:

• Acetaminophen users had lower miscarriage risk compared to NSAID users (adjusted HR 1.45 for NSAIDs vs acetaminophen) 2
• Note that high-dose chronic acetaminophen may carry unidentified NSAID-like risks 1

Critical Clinical Pitfalls

• Do not assume NSAIDs are teratogenic - they are not known to cause structural malformations in humans 1
• The primary risks are functional (implantation failure, ductus closure, renal dysfunction) rather than anatomical 1, 6
• Dose, duration, and gestational timing are all critical factors in determining risk 1, 6
• Self-medication with over-the-counter NSAIDs is common and must be specifically addressed in patient counseling 4, 6